Prudential Financial’s Xenon Pharmaceuticals XENE Stock Holding History

Prudential Financial’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.38M	Buy	39,400 +26,390	+203%	+$1.47M	﹤0.01%	1331
2026 Q1	$757K	Buy	+13,010	New	+$599K	﹤0.01%	1694
2025 Q4	–	Sell	-8,850	Closed	-$355K	–	2463
2025 Q3	$355K	Sell	8,850 -38,905	-81%	-$1.37M	﹤0.01%	2055
2025 Q2	$1.53M	Buy	47,755 +8,755	+22%	+$286K	﹤0.01%	1497
2025 Q1	$1.31M	Hold	39,000	–	–	﹤0.01%	1470
2024 Q4	$1.53M	Buy	39,000 +24,956	+178%	+$1.03M	﹤0.01%	1416
2024 Q3	$553K	Sell	14,044 -37,956	-73%	-$1.53M	﹤0.01%	2169
2024 Q2	$2.03M	Sell	52,000 -7,000	-12%	-$280K	﹤0.01%	1428
2024 Q1	$2.54M	Hold	59,000	–	–	﹤0.01%	1301
2023 Q4	$2.72M	Buy	59,000 +32,000	+119%	+$1.13M	﹤0.01%	1245
2023 Q3	$954K	Buy	+27,000	New	+$1.01M	﹤0.01%	1789

Other funds holding XENE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prudential Financial's XENE Position: Q2 2026 in Review

Prudential Financial increased its Xenon Pharmaceuticals (XENE) stake by 203% in Q2 2026, buying an estimated $1.47M and bringing the position to 39,400 shares worth $2.38M. The position accounts for ﹤0.01% of the portfolio, ranked #1331.

Prudential Financial first reported a position in XENE in Q3 2023 and has held it in 11 quarters since. The position peaked at $2.72M in Q4 2023. 207 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Prudential Financial held 39,400 shares of Xenon Pharmaceuticals worth $2.38M as of Q2 2026.
Prudential Financial bought 26,390 Xenon Pharmaceuticals shares in Q2 2026, an estimated $1.47M.
Xenon Pharmaceuticals made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #1331 holding.
Prudential Financial first reported a position in Xenon Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
Prudential Financial's Xenon Pharmaceuticals position peaked at $2.72M in Q4 2023.
207 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.